RecruitingPhase 1NCT07433062

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Sponsor

AstraZeneca

Enrollment

28 participants

Start Date

Jan 14, 2026

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes Mellitus

Summary

The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how a new experimental drug called AZD6793 affects how metformin (a common diabetes tablet) moves through the body, and how it influences blood sugar levels, in people with type 2 diabetes. **You may be eligible if...** - You have been diagnosed with type 2 diabetes by a doctor - You have been taking 2000 mg of metformin daily at a stable dose for at least 3 months - Your blood sugar control has been stable (no change in diabetes treatment for 3 months) - Your HbA1c (a 3-month blood sugar average) is 8.5% or below - Your BMI is between 18.5 and 35 **You may NOT be eligible if...** - You have type 1 diabetes - You have significant kidney, liver, or heart problems - You are on insulin or other diabetes medications besides metformin - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAZD6793

Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 (Treatment A).

DRUGAZD6793 Placebo

Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 placebo (Treatment B).

Locations(1)

Research Site

Neuss, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07433062

Related Trials

POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.

NCT074331921 location

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

NCT058814471 location

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT0735105836 locations

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

NCT072325371 location

A Study of Glycemic Control in Left Ventricular Assist

NCT059331611 location